Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Receivables (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Receivables for 16 consecutive years, with $371000.0 as the latest value for Q4 2025.

  • For Q4 2025, Receivables fell 91.93% year-over-year to $371000.0; the TTM value through Dec 2025 reached $371000.0, down 91.93%, while the annual FY2025 figure was $371000.0, 91.93% down from the prior year.
  • Receivables hit $371000.0 in Q4 2025 for Sangamo Therapeutics, down from $523000.0 in the prior quarter.
  • Across five years, Receivables topped out at $20.5 million in Q3 2024 and bottomed at $366000.0 in Q1 2025.
  • Average Receivables over 5 years is $5.4 million, with a median of $4.9 million recorded in 2023.
  • Year-over-year, Receivables skyrocketed 290.55% in 2024 and then plummeted 97.45% in 2025.
  • Sangamo Therapeutics' Receivables stood at $6.4 million in 2021, then dropped by 29.36% to $4.5 million in 2022, then tumbled by 70.49% to $1.3 million in 2023, then surged by 246.91% to $4.6 million in 2024, then tumbled by 91.93% to $371000.0 in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $371000.0, $523000.0, and $372000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.